Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 51.09% is in line with its 5-year average of 53.69%, around the middle of its 5-year range (23.31%–87.31%).
As of the fiscal period ended Tuesday, June 30, 2026. 28.43% below its 12-month average of 71.39%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 51.09%.
DEBT TO ASSETS RATIO
51.09%
DEBT TO ASSETS RATIO AVG TTM
71.39%
DEBT TO ASSETS RATIO AVG 3Y
56.58%
DEBT TO ASSETS RATIO AVG 5Y
53.69%
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-28.43%
CURRENT VS 3Y AVG
-9.70%
CURRENT VS 5Y AVG
-4.84%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.09%
median of 847 covered companies
CURRENT VS SECTOR MEDIAN
+56669.85%
vs the sector median at left
Phathom Pharmaceuticals, Inc.
Market Cap
$530.69M
Debt to Assets Ratio
51.09%
TTM Avg
71.39%
3Y Avg
56.58%
5Y Avg
53.69%
Market Cap
$531.13M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$526.81M
Debt to Assets Ratio
0.19%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$534.74M
Debt to Assets Ratio
0.02%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$535.61M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$539.49M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$540.41M
Debt to Assets Ratio
0.01%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$520.89M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Phathom Pharmaceuticals, Inc. (PHAT) | $530.69M | 51.09% | 71.39% | 56.58% | 53.69% |
| Monopar Therapeutics Inc. (MNPR)vs › | $531.13M | 0.00% | N/A | N/A | N/A |
| ProKidney Corp. (PROK)vs › | $533.70M | 0.01% | N/A | N/A | N/A |
| BlossomHill Therapeutics, Inc. (BLSM)vs › | $526.81M | 0.19% | N/A | N/A | N/A |
| Delcath Systems, Inc. (DCTH)vs › | $534.74M | 0.02% | N/A | N/A | N/A |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $535.61M | 0.00% | N/A | N/A | N/A |
| Nuvectis Pharma, Inc. (NVCT)vs › | $539.49M | 0.00% | N/A | N/A | N/A |
| Shattuck Labs, Inc. (STTK)vs › | $540.41M | 0.01% | N/A | N/A | N/A |
| Immix Biopharma, Inc. (IMMX)vs › | $520.89M | 0.00% | N/A | N/A | N/A |
| Altimmune, Inc. (ALT)vs › | $515.36M | 0.07% | N/A | N/A | N/A |
Debt/Assets
51.1%
Debt/Equity
N/A
Current Ratio
1.92
Interest Coverage
-2.4x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 51.09% |
| 2026-03-31 | 54.50% |
| 2025-12-31 | 81.73% |
| 2025-09-30 | 87.31% |
| 2025-06-30 | 82.31% |
| 2025-03-31 | 69.19% |
| 2024-12-31 | 53.37% |
| 2024-09-30 | 45.58% |
| 2024-06-30 | 54.88% |
| 2024-03-31 | 42.09% |
| 2023-12-31 | 33.59% |
| 2023-09-30 | 42.45% |
| 2023-06-30 | 37.47% |
| 2023-03-31 | 68.26% |
| 2022-12-31 | 58.90% |
| 2022-09-30 | 47.45% |
| 2022-06-30 | 44.24% |
| 2022-03-31 | 62.13% |
| 2021-12-31 | 48.22% |
| 2021-09-30 | 39.44% |
| 2021-06-30 | 23.31% |
| 2021-03-31 | 20.20% |
| 2020-12-31 | 16.61% |
| 2020-09-30 | 21.28% |
| 2020-06-30 | 19.35% |
| 2020-03-31 | 17.68% |
| 2019-12-31 | 9.17% |
| 2019-09-30 | 147.84% |
| 2019-06-30 | 135.71% |
| 2018-12-31 | 216.19% |
